Free Papers

First Results with a Refractive Segmental Blue Light Filter Low Add EDOF (+2.0D Add) IOL

Free Paper Details

First Author: L.Beckers GERMANY

Co Author(s):    D. Breyer   H. Kaymak   K. Klabe   M. Kirca   F. Kretz   G. Auffarth     

Abstract Details

Purpose:

Until now there exists no refractive segmental low add EDOF IOL with a blue light filter and near add of +2.0D. Therefore, the aim of this investigation was to evaluate the clinical outcomes in patients implanted with this EDOF IOL with a blue light filter.

Setting:

All surgeries were performed by one surgeon at the Breyer-Kaymak-Klabe Eye Surgery and Premium Eyes in Duesseldorf, Germany, member of the International Vision Correction Research Center (IVCRC.net).

Methods:

20 eyes of 10 patients with cataract and expected postoperative corneal astigmatism of under -0.75D were included. In all eyes, a new low add EDOF IOL with +2.0D addition (Visiotis Progress+; IOL-Expert, Germany) was implanted. We assessed defocus capacity after 3 months postoperatively and compared it with defocus curves of other EDOF IOL. Halo and glare phenomena were evaluated by a patient questionnaire.

Results:

The defocus curve showed better intermediate and near vision compared to monofocal IOL and other refractive EDOF IOL. Evaluation of the patient questionnaire indicated less halo & glare phenomena than in diffractive trifocal MIOL and bifocal EDOF IOL.

Conclusions:

Visiotis Progress provides a new optical design. Independence from glasses with less halo and glare than trifocal MIOL was achieved. We implanted this EDOF IOL as Mini Monovision. Thus, the patients can see far, work in PC and laptop distance and read usual book- and newspaper print without glasses without suffering from photopic phenomena. We also implant this EDOF IOL in the Duesseldorf Formula mode as blended vision (target refraction in dominant eye is emmetropia and in the non-dominant eye -1.5D). This even enables patients to read small print.

Financial Disclosure:

... gains financially from product or procedure presented, ... travel has been funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a competing company, ... receives consulting fees, retainer, or contract payments from a competing company